


*Intensive Care Units (ICUs): Clinical  
Outcomes, Costs, and Decisionmaking*

November 1984

NTIS order #PB85-145928



---

---

HEALTH TECHNOLOGY CASE STUDY 28

# Intensive Care Units (ICUs)

## Clinical Outcomes, Costs, and Decisionmaking

---

---

NOVEMBER 1984

This case study was performed as a part of OTA'S Assessment of  
Medical Technology and Costs of the Medicare Program

Prepared under contract to OTA by:  
Robert A. Berenson, M.D.

OTA Case Studies are documents containing information on a specific medical technology or area of application that supplements formal OTA assessments. The material is not normally of as immediate policy interest as that in an OTA Report, nor does it present options for Congress to consider.



CONGRESS OF THE UNITED STATES  
Office of Technology Assessment  
Washington, D C 20510

Recommended Citation:

Berenson, R. A., *Intensive Care Units (ICUs): Clinical Outcomes, Costs, and Decisionmaking* (Health Technology Case Study 28), prepared for the Office of Technology Assessment, U.S. Congress, OTA-HCS-28, Washington, DC, November 1984.

Library of Congress Catalog Card Number 84-601138

For sale by the Superintendent of Documents  
U.S. Government Printing Office, Washington, D.C. 20402

# Preface

*Intensive Care Units (ICUs): Clinical Outcomes, Costs, and Decisionmaking*, is Case Study 28 in OTA'S Health Technology Case Study Series. This case study has been prepared in connection with OTA'S project on *Medical Technology and Costs of the Medicare Program*, requested by the House Committee on Energy and Commerce and its Subcommittee on Health and the Environment and the Senate Committee on Finance, Subcommittee on Health. A listing of other case studies in the series is included at the end of this preface.

OTA case studies are designed to fulfill two functions. The primary purpose is to provide OTA with specific information that can be used in forming general conclusions regarding broader policy issues. The first 19 cases in the Health Technology Case Study Series, for example, were conducted in conjunction with OTA'S overall project on *The Implications of Cost-Effectiveness Analysis of Medical Technology*. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of cost-effectiveness or cost-benefit analysis, OTA was able to better analyze the potential contribution that those techniques might make to the management of medical technology and health care costs and quality.

The second function of the case studies is to provide useful information on the specific technologies covered. The design and the funding levels of most of the case studies are such that they should be read primarily in the context of the associated overall OTA projects. Nevertheless, in many instances, the case studies do represent extensive reviews of the literature on the efficacy, safety, and costs of the specific technologies and as such can stand on their own as a useful contribution to the field.

Case studies are prepared in some instances because they have been specifically requested by congressional committees and in others because they have been selected through an extensive review process involving OTA staff and consultations with the congressional staffs, advisory panel to the associated overall project, the Health Program Advisory Committee, and other experts in various fields. Selection criteria were developed to ensure that case studies provide the following:

- examples of types of technologies by func-

tion (preventive, diagnostic, therapeutic, and rehabilitative);

- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (e.g., general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (e.g., cost);
- examples of technologies with associated high costs either because of high volume (for low-cost technologies) or high individual costs;
- examples that could provide information material relating to the broader policy and methodological issues being examined in the particular overall project; and
- examples with sufficient scientific literature.

Case studies are either prepared by OTA staff, commissioned by OTA and performed under contract by experts (generally in academia), or written by OTA staff on the basis of contractors' papers.

OTA subjects each case study to an extensive review process. Initial drafts of cases are reviewed by OTA staff and by members of the advisory panel to the associated project. For commissioned cases, comments *are* provided to authors, along with OTA'S suggestions for revisions. Subsequent drafts are sent by OTA to numerous experts for review and comment. Each case is seen by at least **30** reviewers, and sometimes by **80 or** more outside reviewers. These individuals may be from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists, sociologists, decision analysts, biologists, and so forth, as appropriate, also review the cases.

Although cases are not statements of official OTA position, the review process is designed to satisfy OTA'S concern with each case study's scientific quality and objectivity. During the various stages of the review and revision process, therefore, OTA encourages, and to the extent possible requires, authors to present balanced information and recognize divergent points of view.

## Health Technology Case Study Series<sup>a</sup>

Case Study Series number	Case study title; author(s); OTA publication number <sup>b</sup>	Case Study Series number	Case study title; author(s); OTA publication number <sup>b</sup>
1	Formal Analysis, Policy Formulation, and End-Stage Renal Disease; Richard A. Rettig (OTA-BP-H-9(1)) <sup>c</sup>	14	Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14))
2	The Feasibility of Economic Evaluation of Diagnostic Procedures: The Case of CT Scanning; Judith L. Wagner (OTA-BP-H-9(2))	15	Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15))
3	Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3))	16	The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16))
4	Cost Effectiveness of Automated Multichannel Chemistry Analyzers; Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(4))	17	Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (OTA-BP-H-9(17))
5	Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M Scheffler and Sheldon Rovin (OTA-BP-H-9(5))	18	The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) <sup>d</sup>
6	The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications; Stuart O. Schweitzer and C. C. Scalzi (OTA-Bp-H-9(6))	19	Assessment of Four Common X-Ray Procedures; Judith L. Wagner (OTA-BP-H-9(19)) <sup>e</sup>
7	Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7))	20	Mandatory Passive Restraint Systems in Automobiles: Issues and Evidence; Kenneth E. Warner (OTA-BP-H-15(20)) <sup>f</sup>
8	The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-Bp-H-9(8))	21	Selected Telecommunications Devices for Hearing-Impaired Persons; Virginia W. Stern and Martha Ross Redden (OTA-BP-H-16(21)) <sup>g</sup>
9	The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9))	22	The Effectiveness and Costs of Alcoholism Treatment; Leonard Saxe, Denise Dougherty, Katharine Esty, and Michelle Fine (OTA-HCS-22)
10	The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10))	23	The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis; John C. Langenbrunner (Office of Technology Assessment) (OTA-HCS-23)
11	Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11))	24	Variation in Length of Hospital Stay: Their Relationship to Health Outcomes; Mark R. Chassin (OTA-HCS-24)
12	Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12))	25	Technology and Learning Disabilities; Candis Cousins and Leonard Duhl (OTA-HCS-25)
13	Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13))	26	Assistive Devices for Severe Speech Impairments; Judith Randal (Office of Technology Assessment) (OTA-HCS-26)
		27	Nuclear Magnetic Resonance Imaging Technology: A Clinical, Industrial, and Policy Analysis; Earl P. Steinberg and Alan Cohen (OTA-HCS-27)
		28	Intensive Care Units (ICUs): Clinical Outcomes, Costs, and Decisionmaking; Robert A. Berenson (OTA-HCS-28)

available for sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D. C., 20402, and by the National Technical Information Service, 5285 Port Royal Road, Springfield, Va., 22161. Call OTA's Publishing Office (224-8996) for availability and ordering information.

<sup>b</sup>Original publication numbers appear in parentheses.

<sup>c</sup>The first 17 cases in the series were 17 separately issued cases in *Background Paper #2: Case Studies of Medical Technologies*, prepared in conjunction with OTA's August 1980 report *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

<sup>d</sup>Background Paper #3 to *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

<sup>e</sup>Background Paper #5 to *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

<sup>f</sup>Background paper #1 to OTA's May 1982 report *Technology and Handicapped People*.

<sup>g</sup>Background Paper #2 to *Technology and Handicapped People*.

## OTA Project Staff for Case Study #28

H. David Banta<sup>1</sup> and Roger C. Herdman,<sup>2</sup> *Assistant Director, OTA  
Health and Life Sciences Division*

Clyde J. Behney, *Health Program Manager*

Anne Kesselman Burns, *Project Director*

Pamela Simerly, *Research Assistant*

Virginia Cwalina, *Administrative Assistant*

Beckie I. Erickson,<sup>3</sup> *Secretary/Word Processing Specialist*

Brenda Miller, *PC Specialist*

Jennifer Nelson,<sup>3</sup> *Secretary*

Mary Walls,<sup>4</sup> *Secretary*

---

<sup>1</sup>Until August 1983.

<sup>2</sup>Since December 1983.

<sup>3</sup>Since January 1984.

<sup>4</sup>Until January 1984.

# Medical Technology and Costs of the Medicare Program Advisory Panel

Stuart Altman, Panel Chair  
Dean, Florence Heller School, Brandeis University

Frank Baker  
Vice President  
Washington State Hospital Association

Robert Blendon  
Senior Vice President  
The Robert Wood Johnson Foundation

Jerry Cromwell  
President  
Health Economics Research  
Chestnut Hill, MA

Karen Davis  
Chair, Department of Health Policy and  
Management  
School of Hygiene and Public Health  
Johns Hopkins University

Robert Derzon  
Vice President  
Lewin & Associates  
San Francisco, CA

Howard Frazier  
Director  
Center for the Analysis of Health Practices  
Harvard School of Public Health

Clifton Gaus  
President, Foundation for Health Services  
Research  
Washington, DC

Jack Hadley  
Director  
Center for Health Policy Studies  
Georgetown University

Kate Ireland  
Chair, Board of Governors  
Frontier Nursing Service  
Wendover, KY

Judith Lave  
Professor  
Department of Health Economics  
University of Pittsburgh

Mary Marshall  
Delegate  
Virginia House of Delegates

Walter Mc Nerney  
Professor of Health Policy  
J. L. Kellogg Graduate School of Management  
Northwestern University

Morton Miller  
Immediate Past President  
National Health Council  
New York, NY

James Morgan  
Executive Director  
Truman Medical Center  
Kansas City, MO

Seymour Perry  
Deputy Director  
Institute for Health Policy Analysis  
Georgetown University Medical Center

Robert Sigmond  
Director, Community Programs for  
Affordable Health Care  
Advisor on Hospital Affairs Blue Cross/Blue  
Shield Association

Anne Somers  
Professor  
Department of Environmental and  
Community and Family Medicine  
UMDNJ—Rutgers Medical School

Paul Torrens  
School of Public Health  
University of California, Los Angeles

Keith Weikel  
Group Vice President  
AMI  
McLean, VA